ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER

摘要

Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of durvalumab (MEDI4736) or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof. A combination of durvalumab and tremelimumab was effective at treating non-small cell lung cancers characterized as PD-L1- and having a high level of CD8+ tumor-infiltrating lymphocytes.